This uncommon and remarkable feature of D-BMAP18 combined with the enhanced antibacterial activity observed in the presence of DNase, suggests a potential use of D-BMAP18 in combination with hypertonic solutions and/or dornase alfa (recombinant DNase I), which have already been approved for the mucolytic therapy of CF patients [39]. The gene discussed is DNASE1; the disease is cystic fibrosis.